Aytu BioPharma (AYTU) vs Rein Therapeutics (RNTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Aytu BioPharma (AYTU) has outperformed Rein Therapeutics (RNTX) over the past year, gaining 32.3% versus a loss of 77.2%. Over five years, AYTU leads with a -93.2% price change compared with -97.5% for RNTX. Rein Therapeutics is the larger company by market cap ($29.1 million vs $28.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AYTU | RNTX |
|---|---|---|
| Share price | $2.66 | $0.3369 |
| Market cap | $28.91M | $29.06M |
| 1-day change | 0.00% | -8.38% |
| YTD return | +2.31% | -70.96% |
| 1-year return | +32.34% | -77.24% |
| 5-year return | -93.21% | -97.47% |
| Forward P/E | 17.16 | — |
| EPS (TTM) | $-1.78 | $-1.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $57.57M | $0 |
| Revenue growth (YoY) | -13.27% | — |
| Net income (latest FY) | $-14.25M | $-49.87M |
| Gross margin | 63.95% | — |
| Operating margin | -14.44% | — |
| Net margin | -24.76% | — |
| 52-week high | $3.07 | $2.10 |
| 52-week low | $1.75 | $0.284 |
| Distance from 52-week high | -13.36% | -83.96% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +263.53% | +1680.94% |
| Average volume | 141.18K | 586.68K |
| Shares outstanding | 10.87M | 86.27M |
| Employees | 75 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AYTU has outperformed RNTX by 109.6 percentage points over the past year.
About Aytu BioPharma
AYTU stock →Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT A central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 17 years of age; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 15 years of age.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
About Rein Therapeutics
RNTX stock →Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
AYTU vs RNTX FAQ
Which is bigger, Aytu BioPharma or Rein Therapeutics?
Rein Therapeutics (RNTX) is larger, with a market capitalization of $29.06M compared with $28.91M for Aytu BioPharma (AYTU).
Which stock has performed better over the past year, AYTU or RNTX?
AYTU returned +32.34% over the past 12 months, compared with -77.24% for RNTX (price return, excluding dividends). Past performance does not predict future results.
Are Aytu BioPharma and Rein Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.